Back to Browse Journals » Nursing: Research and Reviews » Volume 3

Why people living with HIV/AIDS exclude individuals from their chosen families

Authors Grant JS, Vance DE, White W, Keltner NL, Raper JL

Published Date March 2013 Volume 2013:3 Pages 33—42

DOI http://dx.doi.org/10.2147/NRR.S39504

Received 24 October 2012, Accepted 20 November 2012, Published 12 March 2013

Joan S Grant,1 David E Vance,1 Worawan White,2 Norman L Keltner,1 James L Raper3

1School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, 2Department of Nursing, Pensacola State College, Pensacola, Florida, 3School of Medicine, Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA

Abstract: Health professionals can gain a better understanding of key elements of social support by examining reasons why people living with human immunodeficiency virus/acquired immunodeficiency syndrome (PLWH) exclude individuals from their chosen families (ie, families of choice). Our study identified reasons why PLWH excluded specific individuals from their chosen families. This mixed-method design was drawn from a larger study of 150 PLWH, in which 94 self-reported why they excluded individuals from their chosen families. Physical and emotional distance (n = 64; 68.1%); nonsupport, nonacceptance, and harm (n = 25; 26.6%); conditional caring and trust (n = 22; 23.4%); and no blood/familial relationship (n = 13; 13.8%) were the reasons PLWH excluded individuals from their chosen families. Demographic and personal characteristics were unrelated to these themes, supporting the conclusion that reasons for excluding family members are universal and not dependent on particular participant characteristics. For chosen family relationships to develop and exist, these findings emphasize the value of physical and emotional contact between individuals.

Keywords: families, stigma, social networks, human immunodeficiency virus, acquired immunodeficiency syndrome

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010